Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (SBI)
Filing Type: Form 10-K (Annual Report)
Period Ended: April 30, 2002
Business Stage: Development-stage enterprise with no commercial revenue.
Core Products: SBI is developing three primary product lines based on perfluorocarbon (PFC) and biosensor technology: Oxycyte (synthetic blood substitute), Fluorovent (liquid ventilation for respiratory distress), and an implantable continuous glucose biosensor for diabetics. All products are in the preclinical stage, preparing for Investigational New Drug (IND) applications with the FDA.
Key Financial Metrics
| Metric | Fiscal 2002 | Fiscal 2001 | Fiscal 2000 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(3,487,813) | $(1,672,242) | $(911,339) |
| Net Loss Per Share | $(0.04) | $(0.02) | $(0.01) |
| Total Expenses | $3,618,101 | $2,003,261 | $927,480 |
| Cash and Cash Equivalents | $2,442,015 | $4,250,898 | $5,466,391 |
| Working Capital | $2,352,474 | $4,020,203 | $5,592,016 |
| Total Liabilities | $179,078 | $344,068 | $345,440 |
| Long-Term Debt | $0 | $0 | $0 |
| Accumulated Deficit | $(16,473,393) | $(12,985,580) | $(11,313,338) |
Material Changes vs. Prior Period
- Expense Surge: Total expenses increased 80% to $3.62 million in 2002 compared to $2.00 million in 2001. This was driven primarily by a $1.55 million non-cash compensation expense related to the issuance of stock warrants to financial consultants.
- Research & Development (R&D): R&D expenses rose 68% to $1.31 million, reflecting increased activity in research wages and consulting services as the company prepares for IND submissions.
- Cash Burn: Cash and cash equivalents decreased by $1.81 million (42%) during the year. Net cash used in operating activities was $1.90 million, partially offset by $465,000 in financing proceeds from stock sales and warrant exercises.
- Stock Issuance: The company issued approximately 4.1 million shares of common stock during the year through cash sales, warrant exercises, and prior deposits, increasing the share count to 88.6 million.
Outlook, Risks, and Management Commentary
- Liquidity Runway: Management estimates existing cash resources will fund operations for approximately one year (through April 2003). Substantial additional financing is required to proceed with clinical trials.
- Capital Needs: The company has no committed funding for future clinical trials. Future financing may involve dilutive equity offerings or debt with restrictive covenants.
- Regulatory Risk: All products require FDA approval. There is no assurance that preclinical testing will succeed or that the FDA will grant approval for clinical trials or eventual marketing.
- Competitive Landscape: SBI faces competition from companies with greater resources (e.g., Biopure, Hemosol, Alliance Pharmaceuticals). Some competitors have suspended or terminated similar programs, but others remain in Phase III trials.
- Strategic Partnerships: The company intends to partner with pharmaceutical or medical device companies for funding and commercialization but currently has no binding agreements.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "one-year" cash runway estimate given the high burn rate and lack of revenue.
- Warrant Liability: Confirm the valuation and vesting terms of the 12.5 million warrants issued to consultants, which drove the majority of the 2002 expense increase.
- IND Status: Determine the specific timeline and remaining costs required to file the Investigational New Drug (IND) application for Oxycyte.
- Capital Raising: Assess the feasibility of raising the "substantial" additional capital required for clinical trials in the current market environment.
- Patent Validity: Review the status of the company's perfluorocarbon and biosensor patents to ensure they provide adequate protection against competitors.